10-K: Vicarious Surgical Details Share Structure and Regulatory Path in Annual Filing

Vicarious Surgical's 10-K filing outlines its capital structure, including Class A and Class B common stock, preferred stock, and warrants, while also detailing its regulatory strategy for its surgical robot.

Summary

• Vicarious Surgical is authorized to issue 323 million shares, including 300 million Class A common shares, 22 million Class B common shares, and 1 million preferred shares.
• Class A common stock has one vote per share, while Class B common stock has 20 votes per share.
• Class B common stock is convertible to Class A common stock on a one-to-one basis at the holder's option or upon certain mandatory conversion events.
• As of December 31, 2023, there were 17,248,601 public warrants and 10,400,000 private placement warrants outstanding, each exercisable for one share of Class A common stock at $11.50.
• The company plans to file a de novo application with the FDA for its surgical robot, initially targeting ventral hernia procedures.
• The company estimates 45 million soft tissue abdominal and gynecological surgical procedures are performed annually worldwide that could be addressed with the Vicarious Surgical System.
• The company incurred research and development expenses of $47.6 million and $43.9 million for the years ended December 31, 2023 and 2022, respectively.
• The company had a net loss of $71.1 million and net income of $5.2 million for the years ended December 31, 2023 and 2022, respectively.
• The company had an accumulated deficit of $132.7 million as of December 31, 2023.
• The company had cash and cash equivalents of $52.8 million and short-term investments of $45.4 million as of December 31, 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the technology is promising and addresses a large market, the company is still in the development stage, has not generated revenue, and has incurred significant losses. The need for additional funding and the presence of a material weakness in internal controls add to the uncertainty.

Positives

• The company's surgical robot is designed to address the limitations of existing surgical methods, including open surgery and multi-port robotic systems.
• The company's technology includes proprietary de-coupled actuators, which are intended to enable improved robotic mobility, reduced size, and lower costs.
• The company's system is designed to be mobile and smaller than legacy systems, potentially reducing hospital costs and space requirements.
• The company's system is designed to provide surgeons with human-equivalent motion and a full nine degrees of freedom per robotic arm.
• The company has a large addressable market for its surgical robot, including ventral hernia repair and other procedures.

Negatives

• The company has a limited operating history and has not generated any revenue from sales of its product candidates.
• The company has incurred significant losses since inception and expects to continue to incur significant losses for the next several years.
• The company has identified a material weakness in its internal control over financial reporting.
• The company is subject to extensive government regulation, which could restrict the development, marketing, sale, and distribution of its product candidates.
• The company relies on limited or sole suppliers for some of the materials and components used in its product candidates.
• The company faces significant competition from larger and well-established companies in the medical device industry.
• The company's success depends on market acceptance of its product candidates, which is not guaranteed.

Risks

• The company may need to raise additional funding to develop and commercialize its surgical robot, and this financing may not be available on acceptable terms or at all.
• The company's success depends on market acceptance of its product candidates, and there is no guarantee that it will achieve this.
• The company is highly dependent on key personnel, and the loss of their services could harm the business.
• The company has no experience in marketing and selling its product candidates, and if it is unable to successfully commercialize them, its business will be adversely affected.
• The company is subject to extensive government regulation, which could restrict the development, marketing, sale, and distribution of its product candidates.
• The company may be sued for infringing the intellectual property rights of third parties, which could be costly and time-consuming.
• The company faces the risk of product liability claims and may be subject to damages, fines, penalties, and injunctions.
• The company has identified a material weakness in its internal control over financial reporting, which could affect its ability to report financial results accurately.
• The company's ability to use net operating losses to offset future income may be subject to certain limitations.
• The company could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and other anti-bribery laws.
• The company may experience manufacturing problems or delays that could limit the growth of its revenue or increase its losses.
• The company relies on limited or sole suppliers for some of the materials and components used in its product candidates, and may not be able to find replacements or immediately transition to alternative suppliers.

Future Outlook

The company expects to continue to incur significant losses for at least the next several years as it develops and commercializes its product candidates. The company anticipates that its expenses will increase substantially as it continues to build its sales, marketing, and distribution infrastructure, continues to develop its surgical robot, seeks to identify and acquire additional technologies, and supports its operations as a public company. The company will require additional capital to develop and commercialize its surgical robot and may seek to sell additional equity or debt securities, enter into a credit facility, or seek other forms of third-party funding.

Management Comments

• The company intends to deliver the next generation in robotic-assisted surgery, designed to solve the shortcomings of open surgery, and current laparoscopic and robot-assisted minimally invasive surgery.
• The company believes it has created a more capable surgical robot than those currently available on the market.
• The company intends to offer the Vicarious Surgical System, maintenance, and service support at more attractive pricing to existing legacy systems.

Industry Context

The document highlights the slow adoption of robot-assisted surgery, estimated to be less than 5% of the estimated 45 million addressable abdominal soft-tissue surgical procedures performed worldwide annually. This is due to factors such as significant capital investment, low utilization, limited capabilities, and difficulty of use. The company aims to address these issues with its single-port surgical robot.

Comparison to Industry Standards

• The company's surgical robot is designed to overcome the limitations of existing multi-port robotic systems, which require multiple incisions and have limited degrees of freedom.
• The company's system is designed to be more mobile and smaller than legacy systems, which require dedicated operating rooms and extensive setup times.
• The company's system is designed to provide surgeons with human-equivalent motion and a full nine degrees of freedom per robotic arm, unlike existing systems with limited motion.
• The company's system is designed to provide greater visibility and sensing capabilities than existing systems, with a high-performance stereoscopic camera and 28 sensors per instrument arm.
• The company's system is designed to be more cost-effective than existing legacy robotic systems, with a lower price point and disposable instruments.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of additional shares and warrants.
• Employees may benefit from stock-based compensation and other benefits.
• Customers (hospitals and ambulatory surgical centers) may benefit from a more cost-effective and efficient surgical robot.
• Patients may benefit from improved surgical outcomes and reduced healthcare costs.
• Suppliers may benefit from increased demand for components and materials.

Next Steps

• The company plans to file a de novo application with the FDA for its surgical robot, initially targeting ventral hernia procedures.
• The company intends to expand its indications to include other abdominal surgical applications, such as gynecological, urological, and general surgery uses.
• The company plans to generate recurring revenue through the sale of single-use components.
• The company plans to demonstrate the clinical and financial value proposition of its surgical robot to hospitals and ambulatory surgical centers.
• The company plans to expand its product offerings to include technologies such as virtual reality and AI.
• The company intends to seek regulatory clearances or approvals in Asia, Europe, and the rest of the world to commercialize its surgical robot worldwide.

Key Dates

Keywords

surgical robotics, minimally invasive surgery, single-port surgery, decoupled actuators, ventral hernia, FDA approval, medical device, Class A common stock, Class B common stock, warrants